database / healing
Larazotide
also known as AT-1001
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 9810532. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
GGVLVQPG
Gly-Gly-Val-Leu-Val-Gln-Pro-Gly
- hydrophobic
- positive
- negative
- polar
- aromatic
- glycine
- proline
- cysteine
Computed backbone mass 725.84 Da agrees with PubChem's reported 725.8 Da (Δ 0.04 Da). Two independent sources agree on the primary structure.
Molecular data
| molecular formula | C32H55N9O10 |
|---|---|
| molecular weight | 725.8 Da (PubChem) |
| computed backbone mass | 725.84 Da |
| length | 8 residues |
| net charge (pH 7.4) | 0 |
| mean hydropathy | 0.74 |
| half-life | not characterised |
| delivery route | oral |
| PubChem CID | 9810532 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Tight-junction regulator studied as a zonulin antagonist in intestinal permeability.
Reported targets: tight junction complex
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| intestinal permeability reduction | Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty li… Pediatrics and neonatology 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT05022303 | AT1001 for the Treatment of COVID-19 Related MIS-C | TERMINATED | PHASE2 |
| NCT01218659 | Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Pa | COMPLETED | PHASE3 |
| NCT01853852 | A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escala | COMPLETED | PHASE1 |
| NCT00386490 | Safety of Larazotide Acetate in Healthy Volunteers | COMPLETED | PHASE1 |
| NCT01730482 | A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT10 | COMPLETED | PHASE1 |
Literature (3)
Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model — Pediatrics and neonatology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 40562584 · DOI 10.1016/j.pedneo.2025.01.016
Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide — Science translational medicine 2025
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 40737433 · DOI 10.1126/scitranslmed.adu4284
The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis — JID innovations : skin science from molecules to population health 2025
Atopic dermatitis (AD) is a chronic inflammatory skin condition with evidence of defects in the barrier properties of the epidermis. Changes in the permeability properties of the tight junction have been reported in AD, and reversing this leaky tight junction may be a potential treatment for AD. This study aimed to determine the effect of larazotide, an antagonist of the protease-activated receptor 2, on the permeability and barrier properties of the tight junctions in keratinocyte monolayers. Normal human epithelial keratinocytes were grown in culture on permeable supports. The effects of larazotide on transepithelial resistance and permeability properties of keratinocyte monolayers were studied before and after histamine challenge. Larazotide mitigated the disruptive effect of histamine on epithelial permeability by increasing the electrical resistance and decreasing epithelial permeab…
open access ↗ · PMID 40330848 · DOI 10.1016/j.xjidi.2025.100369
Related
BPC-157
healing · 8 citations
TB-500
healing · 8 citations
Thymosin β4
healing · 8 citations
GHK
healing · 8 citations